<DOC>
	<DOCNO>NCT00046735</DOCNO>
	<brief_summary>To identify maximum tolerate dose ( MTD ) safety CDC-501 give 6-week cycle patient solid tumor refractory standard treatment .</brief_summary>
	<brief_title>Phase 1 Study OF CDC-501 Patients With Solid Tumors</brief_title>
	<detailed_description>Identify maximum tolerate dose ( MTD ) safety CDC-501 give 6-week cycle patient solid tumor refractory standard treatment</detailed_description>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>1 . Patient must understand voluntarily sign informed consent document . 2 . Age 18 year time signing Informed Consent 3 . Histologically cytologically document solid tumor refractory standard/conventional therapy standard/conventional therapy exists . 4 . Patients must least one measurable nonmeasurable lesion accord RECIST Criteria ( Appendix I ) . 5 . Patient ECOG ( Zubrod ) performance status ≤ 2 . 6 . Approximate life expectancy great 3 month . 7 . Laboratory test within range : Absolute neutrophil count ≥ 1,500/μlL Platelet count ≥100,000/μL Serum creatinine ≤1.5 mg/dL Total bilirubin ≤1.5 mg/dL AST ( SGOT ) /ALT ( SGPT ) ≤ 2 x upper limit normal ( ULN ) ≤ 5 x ULN hepatic metastasis present 8 . The following prior treatment allowable protocol : 9 . Radiation , discontinue least 4 week prior treatment protocol Chemotherapy , discontinue least 4 week prior treatment protocol , least 6 week prior treatment protocol prior nitrosurea mitomycinC treatment 10 . Hormonal therapy cancer , discontinue least 4 week prior treatment protocol 11 . Other investigational drug , discontinue least 4 week prior treatment protocol 12 . Surgery , minor surgery occur least 2 week prior treatment protocol , least 4 week since major surgery 13 . Patient must able adhere study visit schedule protocol requirement . 14 . Women childbearing potential ( WCBP ) must negative serum urine pregnancy test within 7 day prior baseline . In addition , sexually active WCBP must agree use adequate contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) . Exclusion Criteria 1 . Myocardial infarction within previous 6 month , unstable angina , symptomatic congestive heart failure , significant uncontrolled cardiac arrhythmia . 2 . Cerebrovascular accident transient ischemic attack , pulmonary embolism , deep vein thrombosis significant thromboembolic event previous 6 month . 3 . Active infection , include know human immunodeficiency virus ( HIV ) positivity acquiredimmunodeficiencysyndrome ( AIDS ) relate illness . 4 . CNS metastases , unless control previous radiation patient neurologically stable . 5 . Any serious medical condition , laboratory abnormality psychiatric illness would prevent patient signing informed consent limit survival le 3 month . 6 . Pregnant nursing females.Female patient childbearing potential unwilling use reliable contraceptive method . 7 . Any condition , include presence laboratory abnormality , opinion Investigator place patient unacceptable risk he/she participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>Revimid</keyword>
	<keyword>CC5013</keyword>
	<keyword>CC-5013</keyword>
</DOC>